



COLLABORATIVE WORKING EXECUTIVE SUMMARY

Project Title: European Network for Innovative Treatment Evaluation for Breast Cancer - EUNITE BC

Anticipated start date: August 2021

Anticipated end date: December 2021

Project description

Identifying heterogeneity in clinical practice, tracking real world treatment pathways and understanding what drives superior outcomes in early breast cancer patients is currently limited. This project is part of the overall EUNITE breast cancer project which aims to work with hospitals across a number of EU countries to leverage existing data to try to improve the patient pathway for early breast cancer.

The EUNITE BC project will utilise existing retrospective data from an established hospital controlled patient event database. This initial phase will consist of data collection, analysis and anonymisation. This will then lead to a series of site based validation and across site benchmarking exercises involving all the participating centres to establish an early breast cancer pathway report that allows comparison between centres and nations.

Organisations involved

Hull University Teaching Hospitals NHS Trust and Royal Free London NHS Foundation Trust are providing their data and expertise in breast cancer. LOGEX Healthcare analytics group will be carrying out the data analysis, and this is funded by Roche Products Ltd.

Project Approach

The project involves the collection and curation of historic data from NHS Trusts involved. LOGEX will create a single data model to allow the data from each individual centre involved in the international project to be analysed, validated and benchmarked in a secure environment. LOGEX will present the results for discussion with representatives from each of the participating centres with the aim to uncover variation and identify potential areas to improve outcomes. All data remains the property of the NHS, and Roche will only see aggregated and anonymized results.

Benefits to Patients

Patients will benefit from the potential identification of variances between centres, driving best practice to improve outcomes and reduce variation in treatment approaches between centres and nations.

Benefits to NHS

Participating hospitals will receive analysis on their individual performance within their early breast cancer treatment pathway and a comparative analysis with other centres involved in the project. This should help identify and drive service efficiencies and deliver better outcomes using this value based healthcare approach.

Benefits to Roche

Roche will benefit from an improved understanding of how early breast cancer patients are treated in the UK. Gaining a better understanding of the costs associated with early breast cancer treatment and the utility of this type of real world evidence collection. Roche will be receiving insights that can help optimise product development and the lifecycle of our early breast cancer portfolio including products, technology, services and other offerings across our Pharma & Diagnostics divisions.

This document has been produced by Roche Products Ltd